A severe case of vasoplegic shock following metformin overdose successfully treated with methylene blue as a last line therapy

BMJ Case Reports

Volumn 2015, Issue , 2015, Pages

  Graham, Rachel Erin ^a   Cartner, Michaela ^a   Winearls, James ^a  

^a GOLD COAST UNIVERSITY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADRENALIN; ANTIBIOTIC AGENT; BICARBONATE; CREATININE; DESVENLAFAXINE; EXENDIN 4; GLICLAZIDE; GLUCOSE; HYDROCORTISONE; HYPERTENSIVE FACTOR; METFORMIN; METHYLENE BLUE; NORADRENALIN; PROSTACYCLIN; UREA; VASOPRESSIN; VASOCONSTRICTOR AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; ADULT; ANAMNESIS; ANION GAP; ARTICLE; ARTIFICIAL VENTILATION; BLOOD GAS TENSION; BODY POSTURE; BRAIN DISEASE; CASE REPORT; CAUCASIAN; CREATININE BLOOD LEVEL; DEPRESSION; DIALYSATE LEVEL; DISEASE COURSE; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FLUID RESUSCITATION; GAS EXCHANGE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEMODIALYSIS; HEMODYNAMIC STRESS; HUMAN; HYPERVOLEMIA; HYPOGLYCEMIA; INTENSIVE CARE; INTUBATION; LACTIC ACIDEMIA; LUNG ARTERY PRESSURE; MALE; MEAN ARTERIAL PRESSURE; METABOLIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PH; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULSE PRESSURE; RENAL REPLACEMENT THERAPY; SEVERE DISTRIBUTIVE SHOCK; SUSTAINED LOW EFFICIENCY DAILY DIALYSIS; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; UREA BLOOD LEVEL; URINE COLOR; VASOPLEGIA; VOMITING; ACIDOSIS; COMPLICATION; FLUID THERAPY; SHOCK;

ACIDOSIS; ADULT; DRUG OVERDOSE; FLUID THERAPY; GLICLAZIDE; HUMANS; MALE; METFORMIN; METHYLENE BLUE; SHOCK; VASOCONSTRICTOR AGENTS; VASOPLEGIA;

EID: 84938904469     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2015-210229     Document Type: Article

References (40)

1. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004;77:496-9.
2. Donati A, Conti G, Loggi S, et al. Does methylene blue administration to septic shock patients affect vascular permability and blood volume? Crit Care Med 2002;30:2271-7.
3. Edmund S, Kwok H, Howes D. Use of methylene blue in sepsis: a systematic review. J Intensive Care Med 2006;21:359-63.
4. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomised, controlled study. Crit Care Med 2001;29:1860-7.
5. Dumbarton T, Minor S, Yeung C, et al. Prolonged methylene blue infusion in refractory septic shock: a case report. Can J Anesth 2011;58:401-5.
6. Boulain T, Achard J, Teboul J, et al. Changes in BP induced by passive leg raising predict response to fluid loading in critically ill patients. Chest 2002;121:1245-52.
7. Andresen M, Dougnac A, Diaz O, et al. Use of methylene blue in patients with refractory septic shock: impact on haemodynamics and gas exchange. J Crit Care 1998;13:164-8.
8. Gachot B, Bedos J, Veber B, et al. Short-term effects of methylene blue on haemodynamics and gas exchange in humans with septic shock. Intensive Care Med 1995;21:1027-31.
9. Schneider F, Lutun P, Hasselmann M, et al. Methylene blue increases systemic vascular resistance in human septic shock: preliminary observations. Intensive Care Med 1992;18:309-11.
10. Weingartner R, Oliveira E, Oliveira ES, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res 1999;32:1505-13.
11. Sud S, Friedrich JO, Taccone P, et al. Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med 2010;36:585-99.
12. Guérin C, Reignier J, Richard J, et al. Prone positioning in severe acute respiratory distress syndrome. The New Eng J of Med 2013;368:2159-68.
13. Clifton J II, Leikin J. Methylene blue. Amer J Ther 2003;10:289-91.
14. Shanmugam G. Vasoplegic syndrome- the role of methylene blue. Eur J Cardiothorac Surg 2005;28:705-10.
15. Jang DH, Nelson LS, Hoffman RS. Methylene blue in the treatment of refractory shock from an amlodipine overdose. Ann Emerg Med 2011;58:565-7.
16. Aggarwal N, Kupfer Y, Seneviratne C, et al. Methylene blue reverses recalcitrant shock in beta-blocker and calcium channel blocker overdose. BMJ Case Rep 2013;2013:pii: bcr2012007402.
17. Fisher J, Taori G, Braitberg G, et al. Methylene blue used in the treatment of refractory shock resulting from drug poisoning. Clin Toxicol 2013;52:63-5.
18. Jang D, Nelson L, Hoffman R. Methylene blue for distributive shock: a potential new use of an old antidote. J Med Toxicol 2013;9:242-9.
19. Pasin L, Umbrello M, Greco T, et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc 2013;15:42-8.
20. Davis BJ, Xie Z, Viollet B, et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006;55:496-505.
21. Plumb B, Parker A, Wong P. Feeling blue with metformin-associated lactic acidosis. BMJ Case Rep 2013;2013:pii: bcr2013008855.
22. Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994;28:34-9.
23. Cobb JP, Natanson C, Hoffman WD, et al. N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med 1992;176:1175-82.
24. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomised, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30.
25. Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxic shock. Cardiovasc Res 1992;26:48-57.
26. Ginimuge P, Jyothi S. Methylene blue: revisited. J Anaesthesiol Clin Pharmacol 2010;26:517-20.
27. Ingeborg WS, Rengelshausen J, Oberwittler H, et al. High absolute oral bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol 2009;65:179-89.
28. Oliveira Neto A, Duarte N, Vicente W, et al. Methylene blue: an effective treatment for contrast medium-induced anaphylaxis. Med Sci Monit 2003;9:CS102-6.
29. Del Duca D, Sheth SS, Clarke AE, et al. Use of methylene blue for catecholamine-refractory vasoplegia from protamine and aprotinin. Ann Thorac Surg 2009;87:640-2.
30. Rodrigues JM, Pazin Filho A, Rodrigues AJ, et al. Methylene blue for clinical anaphylaxis treatment: a case report. Sao Paulo Med J 2007;125:60-2.
31. Weissgerber AJ. Methylene blue for refractory hypotension: a case report. AANA J 2008;76:271-4.
32. Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg 2003;125:426-7.
33. Lo J, Darracq M, Clark R. A review of methylene blue treatment for cardiovascular collapse. J Emerg Med 2014;46:670-9.
34. Juffermans N, Vervloet M, Daemen-Gubbels C, et al. A dose-finding study of methylene blue to inhibit nitric oxide actions in the haemodynamics of human septic shock. Nitric Oxide 2010;22:275-80.
35. Plotkin J, Buell J, Njoku M. Methemoglobinemia associated with dapsone treatment in solid organ transplant recipients: a two-case report and review. Liver Transpl Surg 1997;3:149-52.
36. Dumbarton T, Gorman S, Minor S, et al. Local cutaneous necrosis secondary to a prolonged peripheral infusion of methylene blue in vasodilatory shock. Ann Pharmacother 2012;46:e6.
37. Rowley M, Riutort K, Shapiro D, et al. Methylene-blue associated serotonin syndrome: a 'green' encephalopathy after parathyroidectomy. Neurocrit Care 2009;11:88-93.
38. Evora PR, Jose Rodrigues A, Celotto AC. "Methylene blue should be relegated to rescue use and not as first-line therapy" cannot become a paradigm. J Cardiovasc Anesth 2014;28:11-12.
39. Evora PR. Methylene blue does not have to be considered only as rescue therapy for distributive shock. J Med Toxicol 2013;9:426.
40. The Royal Australian College of General Practitioners. General practice management of type 2 diabetes - 2014-15. Melbourne: The Royal Australian College of General Practitioners and Diabetes Australia, 2014:47-8. (accessed Sep 2014).